Home / 2020 / March / 10

Daily Archives: March 10, 2020

Armenia’s electronic health record journey is strengthened through membership in SNOMED International and commitment to SNOMED CT’s clinical terminology

London, United Kingdom, March 10, 2020 (GLOBE NEWSWIRE) — As 2019 drew to a close, the Republic of Armenia’s Ministry of Health signed on as a Member of the SNOMED International community.

The Ministry of Health of the Republic of Armenia elaborates and implements the policies of the Republic in the healthcare sector.  The Republic holds authority for the implementation of Armenia’s e-Health system, a single information platform supporting stakeholders of the country’s medical institutions, citizens, and the state healthcare providers.  The goal of the system is the usage of modern information and communication technologies, providing high-quality, safe, accessible and cost-effective medical services to the public; Tenets of which SNOMED CT supports in full.

With a roadmap introduced by the Minister of Health at the end of 2017, SNOMED CT is well positioned to support the implementation of Armenia’s unified electronic information system approach through the provision of clinical terminology.  Through the contribution of a structured clinical terminology, Armenia can leverage SNOMED CT to support delivery of projected system outcomes including the accuracy and relevancy of clinical information, a reduction in clinical miscommunication, and the ability to effectively use data to drive system-wide care decisions.

SNOMED CT is the world’s most comprehensive health terminology.  Founded in 2007 by nine charter nations, SNOMED International is a not-for-profit, member-owned and driven international organization.  The addition of Armenia as a Member has grown the organization’s membership reaching further into Eurasia, now representing nine countries in the Asia Pacific region.

“We are exceedingly pleased to be able to play a role in the Republic of Armenia’s national electronic information system implementation”, offers SNOMED International CEO, Don Sweete. “Through Protocol Decision no 43 and a definitive roadmap, Armenia sets its sights to improve the effectiveness, transparency and accuracy of health care interactions for their citizens, something that SNOMED International is proud to take part in progressing.”

Since 2017, the Government of Armenia has dynamically installed e-health system in all hospitals throughout the country.  In this ongoing process to achieve great results, the Ministry of Health of Armenia adopted a policy of integration of the data to be accurate, reliable and complete.  For this reason, Armenia joined SNOMED International as a member country in 2019 to promote health information coding, health research and health records. Future integration and sharing of data will enhance and support clinical decisions and planning health policy.

The Government of Armenia strongly has a belief that integration of SNOMED CT will not only support more accurate clinical decisions, but will also enhance productivity and patient safety.  This is one step forward to unifying different local health systems.

Armenia’s membership heightens the capability for clinical interoperability within the Asia Pacific region as well as leverages knowledge sharing among regional and international counterparts.  SNOMED CT is part of the national infrastructure to ensure the exchange of accurate, relevant and timely information across all the information systems to support direct care, self-care and secondary uses of health information.

To learn more about SNOMED International, SNOMED CT and new Member Armenia, visit www.snomed.org.

About SNOMED International:

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation.

Attachment

Kelly Kuru
SNOMED International
1 416 566 8725
kku@snomed.org

Tamara Minasyan
Ministry of Health, Republic of Armenia
minatama@gmail.com

Algernon Announces Coronavirus Update Featured on BioPub Hosted by Dr. KSS MD PhD

VANCOUVER, British Columbia, March 10, 2020 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that BioPub recently hosted an interview by Dr. KSS of the Company’s CEO and CSO. The 35 minute interview provides additional insight into the Company’s recent developments surrounding COVID-19 (coronavirus) and the potential of NP-120 (Ifenprodil) as a possible therapeutic treatment.

The interview can be accessed through the following link: https://youtu.be/K7y05y_N4ow

The Company invites interested shareholders, investors, members of the media and the public to listen to the update.
 
About BioPub

BioPub.co is a biotech investment discussion website. Our goal is to be the secret weapon and unfair advantage of every subscriber. What you will find is an education including interviews others don’t get and presence at meetings others don’t bother to attend. We promote what we consider best in class companies and follow them closely to ensure that management is executing their business plan faithfully and that development trials proceed as expected. We leverage the knowledge brought to the table by our professional members to see if the products being brought to market make sense financially in a world whose rules are changing daily.

About Algernon Pharmaceuticals Inc. 

Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on advancing its lead compounds for non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD) inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough.

CONTACT INFORMATION

Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

CAUTIONARY DISCLAIMER STATEMENT: No securities regulatory authority or stock exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to the closing of the Offering, product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

GCP Applied Technologies Signs VERIFI® Deal with Singapore Concrete Technology Innovator Pan-United Concrete Pte. Ltd.

Extends global position of VERIFI® in-transit concrete management system through expanded partnership with Singapore’s largest concrete and cement provider

CAMBRIDGE, Mass., March 10, 2020 (GLOBE NEWSWIRE) — GCP Applied Technologies Inc. (NYSE: GCP), a leading global provider of construction products technologies, today announced that it has reached an agreement with Pan-United Concrete Pte. Ltd., a wholly-owned subsidiary of Singapore-listed Pan-United Corporation Ltd., the country’s largest concrete and cement provider. The agreement implements GCP’s VERIFI® in-transit concrete management system for use in more than 300 of Pan-United’s fleet of concrete mixer trucks in the Singapore market.

“Our agreement with Pan-United is an important step in expanding the global reach of our VERIFI® in-transit concrete management system and strengthening our position in the Asia Pacific market,” said Dr. Boudewijn Van Lent, GCP’s EVP of Specialty Construction Chemicals. “Pan-United is a global leader and proven concrete technology innovator, and we are pleased to build our partnership and continue to improve the quality, consistency and efficiency of how concrete is delivered.”

The VERIFI® in-transit concrete management system provides sophisticated, automated process monitoring and control during transit from the ready-mix concrete plant to the jobsite by using sensors installed on concrete mixer trucks to monitor, measure and manage concrete properties in-transit. The VERIFI® system offers a new level of concrete quality control and helps increase product consistency from one truck to the next to reduce rejected loads, increase jobsite efficiency and minimize costly project delays. In addition, the technology offers several environmental benefits including the potential for less cement usage and reduced waste as well as increased fuel efficiency.

“The VERIFI® system is a breakthrough innovation in the construction industry. It sets higher standards for concrete quality, workability management and consistency. It also improves the productivity of our operations and demonstrates our commitment to sustainability,” said Mr. Ken Loh, Chief Operating Officer of Pan-United Corporation Ltd. “Pan-United is excited to expand the use of the VERIFI® system in our fleet. This is an important step in leading the way to driving innovation deeper into the concrete industry, while enhancing efficiency and providing sustainable solutions to our customers,” added Mr. Loh.

About GCP Applied Technologies
GCP is a leading global provider of construction products technologies that include admixtures and additives for concrete and cement, the VERIFI® in-transit concrete management system, high-performance waterproofing products, and specialty construction products. GCP products have been used to build some of the world’s most renowned structures. More information is available at www.gcpat.com.

Investor Relations
Joseph DeCristofaro
T +1 617.498.2616
investors@gcpat.com

This announcement contains “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the context of the statement and generally arise when GCP or its management is discussing its beliefs, estimates or expectations. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “will,” “expects,” “estimates,” “suggests,” “anticipates,” “outlook,” “continues,” or similar expressions. These statements are not historical facts or guarantees of future performance but instead represent only the beliefs of GCP and its management at the time the statements were made regarding future events which are subject to certain risks, uncertainties and other factors, many of which are outside GCP’s control. Actual results and outcomes may differ materially from what is expressed or forecast in such forward-looking statements. Forward-looking statements include, without limitation, statements about expected financial positions; results of operations; cash flows; financing plans; business strategy; operating plans; strategic alternatives; capital and other expenditures; competitive positions; growth opportunities for existing products; benefits from new technology and cost reduction initiatives, plans and objectives; and markets for securities. Like other businesses, we are subject to risks and uncertainties that could cause our actual results to differ materially from our projections or that could cause other forward-looking statements to prove incorrect. Factors that could cause actual results to materially differ from those contained in the forward-looking statements, or that could cause other forward-looking statements to prove incorrect, include, without limitation, risks related to: the cyclical and seasonal nature of the industries that GCP serves; foreign operations, especially in emerging regions; changes in currency exchange rates; the cost and availability of raw materials and energy; the effectiveness of GCP’s research and development, new product introductions and growth investments; acquisitions and divestitures of assets and gains and losses from dispositions; developments affecting GCP’s outstanding liquidity and indebtedness, including debt covenants and interest rate exposure; developments affecting GCP’s funded and unfunded pension obligations; warranty and product liability claims; legal proceedings; the inability to establish or maintain certain business relationships and relationships with customers and suppliers or the inability to retain key personnel; the handling of hazardous materials and the costs of compliance with environmental regulations; extreme weather events and natural disasters. These and other factors are identified and described in more detail in GCP’s Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available online at www.sec.gov, and subsequent quarterly reports. Readers are cautioned not to place undue reliance on GCP’s projections and other forward-looking statements, which speak only as of the date thereof. GCP undertakes no obligation to publicly release any revision to its projections and other forward-looking statements contained in this announcement, or to update them to reflect events or circumstances occurring after the date of this announcement.

Two New Liver Fibrosis Rodent Models Launched by Crown Bioscience

SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) — Crown Bioscience today announced the launch of two new liver fibrosis rodent models, allowing more rapid and cost-effective evaluation of the preclinical effects of NASH and anti-fibrotic treatments on acute liver injury, advanced fibrosis, and/or fibrosis reversal.

The two models encompass fibrosis induced by carbon tetrachloride and a new cholesterol-added, choline-deficient fibrosis (CCDF) diet. The launch of these models furthers CrownBio’s commitment to progressing NASH drug development by providing a wider breadth of preclinical platforms.

The new CCDF diet is a modification of the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) currently in preclinical use, featuring lower fat composition and added cholesterol. The resulting Wistar rat and C57BL/6 murine models display more severe liver injury than rodents on CDAHFD, with fibrosis observed in only six to nine weeks, and without the significant weight loss commonly observed in conventional chemical and nutritional deficit models.

Carbon tetrachloride induction provides rapid fibrosis models, allowing time and cost savings on preclinical studies compared with overnutrition and nutritional deficit models. Severe fibrosis is observed in as little as four weeks in C57BL/6 and Balb/c murine models, compared with 16 weeks or longer for industry standard overnutrition diets.

“Fibrosis is associated with more severe forms of NASH, so developing new platforms to model this disease aspect can help the patient populations worst affected by this silent disease,” said Dr. Jim Wang, Senior Vice President of Cardiovascular and Metabolic Disease at CrownBio. “These new models, along with other liver disease models including MS-NASH and CCl4 induced or modified rodent models, as well as NHP models, add to our vision of establishing a market-leading platform of highly translational models to accelerate NASH drug discovery.”

Characterization data on the novel CCDF model induced in the Wistar rat will be presented by CrownBio at the upcoming NASH Summit in Boston. The poster titled: ‘A Cholesterol Added, Choline Deficient Fibrogenic Diet Aggravates Liver Injury and Hepatic Steatosis in Wistar Rats’ will be presented to the NASH scientific community on May 5th 2020.

Later this year, CrownBio will also present data on a new diet-enhanced NHP model of liver steatosis, lipidemia, and insulin resistance, further enhancing the range of models available to NASH drug developers. Such advancements will allow the evaluation of potential therapeutics that reduce liver triglycerides and improve insulin resistance in models closely recapitulating human metabolic disease.

About Crown Bioscience Inc.

Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development services company providing translational platforms to advance oncology, metabolic disease, and inflammation research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

For more information visit:

https://www.crownbio.com
https://www.jsrlifesciences.com

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
pr@crownbio.com

Five Companies Join Membership Ranks to End Plastic Waste

SINGAPORE, March 10, 2020 /PRNewswire/ — The Alliance to End Plastic Waste, a global not-for-profit organization with a bold vision to end plastic waste in the environment, announced five companies joining its membership ranks. The new members are Ampacet Corporation, Esenttia S.A., Honeywell UOP, INDEVCO sal., and Red Avenue New Materials Group Co., Ltd.

Alliance to End Plastic Waste Logo

“Our member companies from across the value chain have nearly doubled since we launched in January 2019. In just one year, our membership has grown to 47 companies raising USD1 billion. These companies are standing up and doing their part to help end plastic waste in the environment,” said Jacob Duer, President and CEO of the Alliance. “We know plastic waste does not belong in our environment and the new companies joining will bring unique expertise that strengthens our ability to confront and find solutions to this global challenge.”

The Ampacet Corporation, with over 2,000 people worldwide operating technical and color development centers and manufacturing sites in 18 countries, is committed to innovative, cost-effective and sustainable solutions. Alvaro Mendoza, Chief Executive Officer & President of Ampacet said, “Taking care of our planet is no longer a choice, but a responsibility that we embrace.  We are using fewer natural resources to create higher performance and more sustainable products, solutions and services for our customers including some of the world’s most successful and recognizable brands.” Ampacet is partnering with customers and suppliers in simple and efficient ways, which allows them to imagine and develop products that improve the quality of life.

Headquartered in Colombia, Esenttia S.A., part of the Ecopetrol Business Group, is dedicated to the production and commercialization of raw materials for the plastics industry. Juan Diego Mejía, President of Esenttia said, “Joining the Alliance is a huge step towards offering community solutions and alternatives for recycling and reuse of plastics. We want to promote actions for a circular economy and as a manufacturer of raw material, there is a responsibility to the recovery and sustainability of the environment. As part of the Alliance, we can collectively inspire the culture of recycling and transformation of materials into new products that raise the quality of life of our societies.”

Honeywell UOP, the leading international supplier and licensor of process technology, catalysts, adsorbents, equipment, and consulting services has also pledged its membership with the Alliance. “Honeywell is committed to creating sustainable technologies that make our world a better place to live — whether raising the standard of living for billions of people, improving energy efficiency or lowering environmental impact,” said John Gugel, President of Honeywell UOP. “Joining the Alliance to End Plastic Waste is just one of the steps we are taking to demonstrate our support to end plastic waste and contribute to creating a plastic circular economy. We are proud to be part of this effort and look forward to working with other member companies.”

As a diversified and international group of manufacturing companies headquartered in Lebanon, a major driver for INDEVCO is integrating environmental sustainability in its operations, from raw material and energy efficiency to waste management and emission reduction. “Our responsibility is to protect the future, preserve resources, and secure continuity for the next generation. Today, sustainability has come to the forefront of global concerns with plastics taking the limelight. However, we know the value that plastics offer in terms of sustainability. Finding and implementing solutions to avoid plastics in the waste stream is critical, and we look forward to join hands with the Alliance members to transform the plastics industry and end plastic waste,” said Marwan Frem, Board Member of INDEVCO.

Joining the Alliance from China is Red Avenue New Materials Group Co., Ltd a Shanghai-based global material manufacturing and service provider. Denny Zhang, Chairman of the Board said, “Making our planet greener and safer is our goal. Being a member of the Alliance, we are acting to help reduce plastic waste and we hope to call on more Chinese companies to join this mission. The commitment to end plastic waste means carrying out product development that protect the environment and this includes biology-based materials and degradable material – materials that make the earth better.”

About our new members companies, please visit:
www.ampacet.com
www.esenttia.co
www.uop.com
www.indevcogroup.com
www.rachem.com

About the Alliance

The Alliance to End Plastic Waste is a global not-for-profit organization partnering with government, environmental and economic development NGOs and communities around the world to address the challenge to end plastic waste in the environment. Through programs and partnerships, we are focused on solutions in four core areas: infrastructure, innovation, education and engagement, and clean up. As of March 2020, the Alliance has 47 member companies representing global companies and organizations across the value chain.

For more information, please visit www.endplasticwaste.org

Media Contact:

Jessica Lee
media@endplasticwaste.org

Logo – https://mma.prnewswire.com/media/1121969/AEPW_logo.jpg

Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development

  • CEPI to provide an initial $4 million to accelerate vaccine development to prepare for Phase 1
  • Multiple vaccine candidates being tested in preclinical studies prior to advancing to human trials
  • Phase 1 clinical trial expected to initiate in late spring of 2020

GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Coalition for Epidemic Preparedness (CEPI) awarded an initial funding of $4 million to support Novavax’ efforts to develop a COVID-19 vaccine. CEPI and Novavax are having ongoing discussions on additional funding from CEPI to address Novavax’ costs through Phase 1.

“This first stage of funding from CEPI is critical to enable ongoing development of our COVID-19 vaccine candidates,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We commend CEPI for its role as a vital partner to bridge the funding gap for innovative biotech companies like Novavax, which have robust vaccine technology platforms. Novavax is working tirelessly to create a vaccine against this growing epidemic.”

Novavax has produced and is currently assessing multiple recombinant nanoparticle vaccine candidates in animal models prior to advancing to clinical trials. Initiation of Phase1 clinical testing is expected in late spring of 2020. Novavax’ COVID-19 vaccine candidates were created with its proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein. Novavax also expects to utilize its proprietary Matrix-M™ adjuvant with its COVID-19 vaccine candidates to enhance immune responses.

“The current crisis shows that we cannot prevent all infectious diseases from emerging. But we can and must double down on developing vaccines,” said Richard Hatchett, Chief Executive Officer of CEPI. “CEPI has moved quickly and urgently to coordinate with global health authorities and vaccine-development partners. CEPI is pleased to be partnering with Novavax to rapidly develop a potential vaccine candidate against the global threat posed by COVID-19.”

Novavax recently entered into an agreement with Emergent BioSolutions, Inc. (Emergent) to provide contract development and manufacturing services, supplying Novavax with vaccine product for preclinical testing and for use in its Phase 1 clinical trial. In addition, this arrangement offers the potential to leverage Emergent’s rapid deployment capabilities and expertise that provide Novavax scalability and capacity to produce vaccine product for future stockpiling. Emergent will utilize its two Baltimore, MD facilities to manufacture drug substance at its Bayview facility, designated by the U.S. Health and Human Services (HHS) as a Center for Innovation in Advanced Development and Manufacturing (CIADM), and drug product at its Camden facility.

About Coronavirus

A new strain of coronavirus first appeared in late 2019 in China before beginning its rapid spread across the globe. The disease, named COVID-19, continues to cause severe pneumonia-like symptoms in many of those infected. Coronaviruses, so named for their “crown-like” appearance, are a large family of viruses that spread from animals to humans and include diseases such as Middle East Respiratory Syndrome (MERS) and SARS in addition to COVID-19. While much remains unknown about the new coronavirus, it is known that the virus can spread via human-to-human transmission before any symptoms appear.

About Matrix-M™

Novavax’ patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has reached over US$750 million of its $1 billion funding target. CEPI’s priority diseases include Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invests in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (e.g. 2019-nCoV). To date, CEPI has committed to investing over $456 million in vaccine and platform development. Learn more at www.cepi.net.

About Novavax

Novavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, is currently in a pivotal Phase 3 clinical trial to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine to demonstrate efficacy in a Phase 3 clinical trial. Novavax recently initiated development of a vaccine program against COVID-19. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2018, and Quarterly Report on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:     

Investors
Novavax, Inc.
Erika Trahan
ir@novavax.com
240-268-2022

Westwicke
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

ISSI Launches New Analog Mixed Signal Division; Lumissil Microsystems

As a new division of ISSI, Lumissil Microsystems will focus on the design and marketing of Analog & Mixed Signal Semiconductors

MILPITAS, Calif., March 10, 2020 (GLOBE NEWSWIRE) — Integrated Silicon Solution, Inc. (ISSI), a leader in advanced memory and analog IC solutions, announced today the launch of the Analog and Mixed Signal products division with a new name, logo, brand identity and website (www.lumissil.com) to better focus on the product lines serving the markets of Lighting, Sense, Power, Connectivity and Control.  “The new division – Lumissil Microsystems – consolidates our Analog & Mixed Signal product portfolio strengthening our market position while still operating under ISSI entity,” said Ven Shan, Vice President of Lumissil division of ISSI. “As a new division focusing on Analog & Mixed Signal Products, Lumissil continues ISSI’s commitment to long term product support and high quality standards.”

The new Lumissil division will report to ISSI’s Executive management and continue to share G&A, Operations, Finance, MIS, HR, Legal and Quality organizations, however; Lumissil will have its own independent R&D, dedicated Sales, Marketing and Business Development personnel.  There will be no changes in quality and operation structures, manufacturing flow or sub-contractors for all Analog & Mixed Signal products. All customer related transactions will remain with ISSI, without any changes.

“This is a major milestone for ISSI, which highlights our strategic focus in our Analog & Mixed signal products,” said KY Han, CEO of ISSI. “The new Lumissil branding perfectly illustrates our commitment to growing the product portfolio and markets.”

About Lumissil Microsystems
Lumissil Microsystems is the Analog & Mixed signal division of ISSI. Lumissil Microsystems’ primary products are LED drivers for low to mid-power RGB color mixing and high power lighting applications. Other products include Audio, Sensors and Applications Specific Micro controllers and Networking semiconductor ICs. Visit our web site at http://www.lumissil.com.

About Integrated Silicon Solution, Inc. (ISSI)
ISSI is a fabless semiconductor company that designs, develops and markets high performance integrated circuits for the following key markets: (i) automotive, (ii) communications, (iii) industrial, and medical, and (iv) digital consumer. ISSI’s primary products are SRAM, DRAM, Flash memory which includes NOR flash, NAND flash and managed NAND solutions (eMMC), and Analog and Mixed signal integrated circuits. ISSI provides high-quality semiconductor products and has been a committed long-term supplier of integrated circuit products. ISSI is headquartered in Silicon Valley with worldwide offices in Taiwan, Japan, Singapore, China, Europe, Hong Kong, India, and Korea. Visit our web site at http://www.issi.com/

Integrated Silicon Solution, Inc.

Ven Shan Aaron Reynoso
P: 408-969-4622 P: 408-969-5141
vshan@lumissil.com areynoso@lumissil.com